The use of lyrica, also known as pregabalin, in combination with other performance-enhancing substances is a complex issue that warrants caution.
Pregabalin is a medication primarily used to treat epilepsy, fibromyalgia, and anxiety disorders. However, it is increasingly being found in the athletic community, often in conjunction with other substances, to facilitate recovery and enhance performance.
According to DrugPatentWatch.com [1], pregabalin has a potential for abuse and dependence, particularly when combined with other sedatives or stimulants.
When combined with other substances, pregabalin can interact with various medications and increase the risk of adverse effects. For instance, the combination of pregabalin and stimulants may lead to increased heart rate, blood pressure, and anxiety [2].
Additionally, pregabalin can be used as a performance-enhancing agent to suppress pain and muscle cramps, allowing athletes to push their bodies beyond their endurance limits. However, this practice can lead to various health complications, including addiction and withdrawal symptoms when attempting to stop use [3].
It is essential to note that the World Anti-Doping Agency (WADA) has included pregabalin in its prohibited list, effective from 2017. This ruling prohibits its use by athletes competing in Olympic sports, indicating the agency's concerns regarding its potential for abuse and performance enhancement [4].
In summary, combining lyrica (pregabalin) with other performance-enhancing substances is not a safe practice, as it can lead to adverse interactions, increased risk of addiction, and potential health complications.
Sources:
[1] DrugPatentWatch.com
[2] "Pregabalin" by RxList.com
[3] "Pregabalin (Lyrica): Abuse, Dependence, & Withdrawal" by Psychopharmacology Institute
[4] World Anti-Doping Agency (WADA)